WELCOME
1B The Causeway, Goring By Sea, Worthing, BN12 6FA
Current time is 20:01 - Sorry, we're closed
Telephone: 01903 243351
Fax: 01903 705804 ( This will be permanently unavailable as of 1st April 2020)
Cancellation Line: 01903 705855 (Please leave a message)
ALERTS!
Medication Alerts
The following medication is currently having supply issues, please take this into consideration when ordering your next prescription.
| Medication | Strength | How is it affected? | Information from | Recommendation | Date |
|---|---|---|---|---|---|
| Ativan® (lorazepam) | 4mg/ml solution for injection | Out of stock from w/c 27th April until w/c 15th June 2020. | Clinicians offered alternative medication to prescribe | 28/04/20 | |
| Acetazolamide SR | 250mg capsules | Out of stock until the end of July 2020
Acetazolamide immediate release 250mg tablets remain available. |
Department of Health | Clinicians to consider prescribing acetazolamide immediate release 250mg tablets | 14/04/20 |
| UK licensed Konakion | MM Paediatric | Out of stock until the end of May 2020 | Department of Health | Clinicians to consider prescribing unlicensed Konakion MM Paediatric | 14/04/20 |
| Ranitidine All Oral Formulation. | Ranitidine 75mg, 150mg and 300mg tablets • Ranitidine 150mg and 300mg effervescent tablets • Ranitidine 150mg/5ml oral solution • Ranitidine 75mg/5ml oral solution |
An investigation by the Swiss and German regulatory agencies and the FDA, has identified a contaminant, Nnitrosodimethylamine (NDMA), a probable human carcinogen, in samples of ranitidine active substance. Several ranitidine products manufactured for the UK market may contain this active substance contaminated with NDMA. The MHRA has requested that all UK manufacturers using active ingredient from this source quarantine all stock whilst further investigations are ongoing. To date, one supplier, GSK, has undertaken a Class 2 recall of all their ranitidine products. MHRA is continuing to investigate the issue alongside the European Medicines Agency (EMA). Currently all but three UK manufacturers are affected by this situation, however this may change as the MHRA and EMA continue their investigations. There are insufficient supplies available from the unaffected manufacturers to continue to support current usage of oral ranitidine in the UK. Very limited supplies of unaffected oral ranitidine products may remain available and therefore the majority of patients will need to be switched to alternative products. This issue is affecting supplies globally. |
MHRA | Please consult your GP | 16/10/2019 |
If you have any questions about the above, please contact the surgery (after 11 am) or speak to a local pharmacy.
